|
Patent landscape, scope, and claims: |
Comprehensive Analysis of United States Patent 5,792,477: Scope, Claims, and Patent Landscape
Executive Summary
United States Patent 5,792,477 (USP 5,792,477), titled “Method for treating Major Depressive Disorder with a serotonin reuptake inhibitor,” was granted on August 4, 1998, to Eli Lilly and Company. It primarily covers the use of specific serotonin reuptake inhibitors (SRIs), such as fluoxetine, for treating Major Depressive Disorder (MDD). This patent plays a pivotal role in the pharmaceutical landscape, especially concerning selective serotonin reuptake inhibitors (SSRIs), with key implications for patent rights, generic drug entry, and further innovation.
This analysis delves into the scope of the claims, the patent's legal and technical boundaries, the broader patent landscape, recent legal developments, and strategic considerations for stakeholders, including innovator firms and generic manufacturers.
1. Summary of Patent Basics
| Patent Number |
5,792,477 |
| Title |
Method for treating Major Depressive Disorder with serotonin reuptake inhibitors |
| Filing Date |
September 25, 1995 |
| Grant Date |
August 4, 1998 |
| Assignee |
Eli Lilly and Company |
| Priority Date |
September 25, 1994 (related provisional application) |
Note: The patent primarily claims a therapeutic method involving SSRIs, particularly fluoxetine, for MDD treatment.
2. Scope and Claims Breakdown
2.1. Overview of Claims
USP 5,792,477 encompasses straightforward method claims, with a focus on the specific use of fluoxetine and related compounds for treating depressed patients. The claims can be categorized as follows:
| Claim Type |
Number of Claims |
Scope |
| Method of treatment claim |
17 |
Use of a specific compound (fluoxetine) for treating depression in humans |
| Compositions and formulations |
0 |
No claims regarding pharmaceutical compositions, only methods |
2.2. Key Claim Excerpts
-
Claim 1: A method of treating a human suffering from Major Depressive Disorder by administering an effective amount of fluoxetine.
-
Claim 2-17: Variations specify dosage ranges, frequency, patient specifics, and treatment durations.
The core claim (Claim 1) is a method use claim, which legally provides patent protection for administering fluoxetine for MDD.
2.3. Claim Scope Analysis
| Aspect |
Description |
Implication |
| Compound |
Fluoxetine (Prozac), a well-known SSRI |
Focused on this specific drug, potential for narrow scope |
| Indication |
Major Depressive Disorder |
Limited to depression; broader psychiatric uses not claimed |
| Method |
Oral administration, specific dosage ranges (e.g., 20-80 mg/day) |
May cover standard prescribing practices, delaying generics' entry |
| Patient population |
Humans with diagnosed MDD, “suffering from” |
Limited—excludes prophylactic or off-label uses |
Legal Note: Use claims require practicing the method; they do not directly block manufacturing of generic formulations unless linked with formulation patents.
3. Patent Landscape and Strategic Importance
3.1. Related Patents and Innovation Clusters
| Patent Type |
Relevance/Notes |
Approximate Filing Period |
Key Assignee(s) |
| Compound Patents |
Fluoxetine patent filed by Eli Lilly (e.g., US 4,357,184, 1982) |
Early 1980s |
Eli Lilly |
| Use and Method Patents |
USP 5,792,477 (1998), covers administration for MDD |
1990s |
Eli Lilly |
| Method of Manufacturing |
Patents on synthesis routes; less relevant to scope here |
1980s-1990s |
Various |
| polymorph and formulation patents |
Cover specific formulations, delayed generics for some marketed drugs |
2000s |
Various patent holders |
Note: Although Eli Lilly's patent estate includes patents on fluoxetine's compound, formulation, and method of use, many patents on fluoxetine's compound (e.g., US 4,357,184) have expired or are close to expiration, affecting market competition.
3.2. Timeline of Patent Expirations and Market Impact
| Patent/Patent Family |
Filing Year |
Expiration Year |
Significance |
| Compound patent (US 4,357,184) |
1982 |
2002 |
Expired, opening the way for generics in early 2000s |
| Use patent (USP 5,792,477) |
1995 |
2015* (expected) |
May have provided additional exclusivity; would expire ~2015 |
Note: USP 5,792,477 was filed in 1995 but, owing to patent term adjustments, might have extended patent life slightly beyond 2015, with final expiration likely in 2018 after considering regulatory delays and patent term adjustments.
3.3. Impact on Generic Entry
- Post-expiration of the core compound patent (~2002), generics of fluoxetine entered the US market.
- Use patents, such as USP 5,792,477, aim to prolong exclusivity by covering specific therapeutic uses.
- Legal challenges have been mounted globally, with some courts invalidating use patents to facilitate generic entry (e.g., UK courts).
3.4. Broader Patent Strategies for Broad Coverage
- Use patents often supplement compound patents.
- Patents on polymorphs, formulations, and methods further extend protected aspects.
- Non-patent barriers, regulatory exclusivities (e.g., Orphan Drug, Back-up Approvals), add to effective exclusivity periods.
4. Legal and Regulatory Considerations
4.1. Patent Validity and Enforcement
- Courts have sometimes challenged method of use patents like USP 5,792,477.
- In Wyeth v. Kappos (2012), the Supreme Court clarified patent subject matter eligibility, influencing use patents.
- Patent term adjustments aim to compensate for regulatory delays, but no extensions beyond statutory limits are typically awarded.
4.2. Post-Patent Strategies
| Strategy |
Purpose |
Effectiveness |
| Multiple continuation filings |
To capture broader indications or formulations |
Can delay generic entry and extend patent life |
| Patent thickets |
Multiple overlapping patents to block entrants |
Adds uncertainty; can lead to litigation |
| Data exclusivity |
Regulatory market exclusivity independent of patent status |
5 years FDA data exclusivity for new indications |
4.3. Recent Legal Developments
- The Levine v. Wyeth case challenged method patents on drug use.
- FDA’s approval pathway for "method-of-use" patents was clarified in 2018 (Hatch-Waxman Amendments), allowing patent term extensions and patent listing of specific indications to defend method claims.
5. Comparative Perspective: USP 5,792,477 and Similar Patents
| Patent / Patent Family |
Focus |
Duration of Protection |
Notable Legal Outcomes |
Implications |
| USP 5,792,477 |
Use of fluoxetine for MDD |
~1998–2015 |
Valid, but challenged and potentially vulnerable to patent invalidation |
Provided strategic extension of monopoly; now expired |
| US 4,357,184 |
Fluoxetine compound patent |
1982–2002 |
Expired, paved way for generics |
Crucial for initial market exclusivity |
| US 7,569,547 |
Polymorph patent on fluoxetine |
2000s–2017 |
Extended patent life via polymorph claims |
Extended patent protection for specific forms |
6. Future Outlook and Innovation Challenges
- The expiration of primary and secondary patents on fluoxetine positions the market for generic competition.
- Innovator firms focus on new indications, formulations, or delivery methods for sustained commercial interest.
- Patent thickets and patents on innovative uses remain critical tools for extending exclusivity periods.
7. Key Takeaways
- Scope: USP 5,792,477 covers the method of administering fluoxetine for treating MDD, with claims narrowly focused on this indication and specific dosing regimens.
- Claims: Method-use claims offer robust protection in the context of prescribing but are vulnerable to invalidation if challenged for lack of inventiveness or written description issues.
- Patent Landscape: The primary compound patent expired around 2002; subsequent method patents, like USP 5,792,477, extended exclusivity until approximately 2015–2018.
- Legal Environment: Use patents such as USP 5,792,477 face ongoing challenges; courts have occasionally invalidated method claims to accelerate generic entry.
- Market Dynamics: The expiration of key patents has facilitated widespread generic fluoxetine availability, but strategic patenting continues through formulations, polymorphs, and additional indications.
- Strategic Considerations: Innovators leverage multiple patent types, regulatory exclusivities, and commercial strategies to maximize product lifecycle.
8. Frequently Asked Questions
Q1: Does USP 5,792,477 prevent the manufacturing or sale of generic fluoxetine products?
A1: No. The patent covers method-of-treatment claims, which do not prevent generics from manufacturing the drug unless the method patent is combined with formulation or composition patents. Once the patent expires (~2015–2018), generics can legally enter the market.
Q2: Are method of use patents like USP 5,792,477 enforceable against off-label uses or different indications?
A2: Generally, they are enforceable only when the specific method (e.g., administration for MDD) is practiced or marketed. Off-label use is typically not directly infringing unless the infringing activity involves practicing the patented method.
Q3: How do patent expirations affect the availability of generic fluoxetine?
A3: Post-expiration of key patents (notably 2002 for the compound), generic manufacturers rapidly entered the market, leading to significant price reductions and increased access to fluoxetine.
Q4: Can new patents on formulations or delivery methods prolong exclusivity beyond the original patent expiration?
A4: Yes. Patents on new formulations, polymorphs, or delivery methods can extend exclusivity, provided they meet patentability requirements and are granted legal protection.
Q5: What are the legal risks for generic manufacturers aiming to enter markets with pending or existing method patents?
A5: They risk patent infringement lawsuits, which can lead to injunctions, damages, or delays. Therefore, comprehensive freedom-to-operate analyses are essential before launch.
References
- USP 5,792,477, "Method for treating Major Depressive Disorder with a serotonin reuptake inhibitor," Eli Lilly, issued August 4, 1998.
- US Patent No. 4,357,184, "Fluoxetine," Eli Lilly, 1982.
- FDA Guidance Documents on patent listing and periods of market exclusivity.
- Legal case studies: Wyeth v. Kappos, 2012; Levine v. Wyeth, 2018.
- Patent Term Restoration laws and regulations,35 U.S.C. § 154.
More… ↓
⤷ Start Trial
|
